XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Aug 13, 2025 7:30am EDT
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right Aug 04, 2025 7:30am EDT
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right Aug 04, 2025 7:00am EDT
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right Jun 27, 2025 7:30am EDT
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million May 27, 2025 8:01am EDT
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements May 13, 2025 7:30am EDT
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference May 07, 2025 7:30am EDT
